A

Aldeyra Therapeutics
D

ALDX

4.85500
USD
0.04
(0.73%)
Market Closed
Volume
19,186
EPS
-1
Div Yield
-
P/E
-6
Market Cap
289,113,298
Related Instruments
    A
    ADMP
    0
    (0%)
    0.000000 USD
    A
    AGIO
    -1.645
    (-2.97%)
    53.810 USD
    C
    COLL
    -0.640
    (-2.11%)
    29.650 USD
    E
    ESPR
    0.03000
    (1.43%)
    2.13000 USD
    S
    SRPT
    -4.470
    (-4.10%)
    104.600 USD
    More
News

Title: Aldeyra Therapeutics

Sector: Healthcare
Industry: Biotechnology
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.